4.2 Article

Osteoarthritis and Osteoporosis: What Is the Overlap?

期刊

CURRENT RHEUMATOLOGY REPORTS
卷 15, 期 5, 页码 -

出版社

SPRINGER
DOI: 10.1007/s11926-013-0328-0

关键词

Adipokines; Anti-osteoporotic drugs; Bisphosphonates; Body mass index; Bone mineral density; Bone remodelling; Calcitonin; Cartilage; Cathepsin K inhibitors; Estrogen; Fracture; Inflammation; Obesity; Osteoarthritis; Osteoporosis; Strontium ranelate; Subchondral bone; Teriparatide; Overlap

资金

  1. Merck
  2. Sharp Dohme
  3. Eli Lilly and Company
  4. Servier Laboratories
  5. Amgen

向作者/读者索取更多资源

Osteoarthritis (OA) and osteoporosis (OP) are highly prevalent health problems, associated with considerable morbidity. In the past, attention was focused on a supposed inverse relationship between OA and OP, since both disorders usually affect the elderly, but were regarded to rarely coexist in a single person. However, recent studies have revealed several factors which contribute to the pathogenesis of both disorders. These insights might contribute to the development of shared new treatment options in the near future. Increased subchondral bone loss is a characteristic feature of OP and the early stage of OA, and this finding is the rationale for studies on the effect of anti-osteoporotic drugs in OA. In addition, inflammation and unfavourable body composition have been recognized as contributing factors for both disorders. Underweight is a risk factor for OP, while obesity stimulates the development of OA, by mechanical overloading of weight-bearing joints but also by supposed unfavourable effects of adipokines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据